Drug Profile
Research programme: paclitaxel analogues - Xechem
Alternative Names: XCLY 145B1; XCLY 146B2; XCLY 401759Latest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator University of Texas M. D. Anderson Cancer Center; Xechem International
- Developer Xechem International
- Class Alkaloids; Terpenes
- Mechanism of Action Tubulin inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Cancer in USA
- 16 May 2002 Preclinical trials in Cancer in USA (unspecified route)